Sign In
Buy CRDF
$1.40
-0.110 (-7.28%)
At Close: Jun 03, 2026
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
07:37pm, Friday, 08'th Mar 2024
Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving th
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
04:05pm, Wednesday, 06'th Mar 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?
01:01pm, Wednesday, 06'th Mar 2024
Does Cardiff Oncology (CRDF) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
08:40pm, Thursday, 29'th Feb 2024
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.20 per share a year ago.
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
08:06pm, Thursday, 29'th Feb 2024
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
04:07pm, Thursday, 29'th Feb 2024
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite -
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
04:06pm, Thursday, 29'th Feb 2024
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -
Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript
09:11pm, Thursday, 02'nd Nov 2023
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Mark Erlander - CEO Jamie Levine - CFO Conferen
Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Wednesday, 11'th Oct 2023
Cardiff Oncology (CRDF) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks
05:56am, Wednesday, 27'th Sep 2023
Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
07:44pm, Wednesday, 09'th Aug 2023
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.24 per share a year ago.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
09:04pm, Thursday, 02'nd Mar 2023
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 20% and 70.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
08:15am, Monday, 27'th Feb 2023
SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no
Cardiff Oncology to Present at Upcoming Investor Conferences
10:52am, Monday, 21'st Nov 2022
SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,
Cardiff Oncology to Present at the Jefferies London Healthcare Conference
08:15am, Tuesday, 08'th Nov 2022
SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,
